Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
The relative clinical value of immun-oncology treatment, the NNT values of PD1-inhibitor nivolumab and pembrolizumab in metastatic melanoma patients E. Porneczy1 and I. Boncz2 1Chemotherapy-D, National Institute of Oncology, Budapest, Hungary 2Health Insurance, University of Pecs, Pecs, Hungary Background: The immun-oncology innovations of cancer treatment, the PD-1 inhibitor pembro and nivo were registered by EMA for the treatment of metastatic melanoma.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
